Cargando…

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models

Oncolytic virus (OV) as a promising therapeutic agent can selectively infect and kill tumor cells with naturally inherited or engineered properties. Considering the limitations of OVs monotherapy, combination therapy has been widely explored. MEK inhibitor (MEKi) Trametinib is an FDA-approved kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, XuSha, Zhao, Jing, Zhang, Jian V., Wu, Yinglin, Wang, Lei, Chen, Xiaoqing, Ji, Dongmei, Zhou, Grace Guoying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473197/ https://www.ncbi.nlm.nih.gov/pubmed/34578339 http://dx.doi.org/10.3390/v13091758

Ejemplares similares

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models
por: Wu, Yinglin, et al.
Publicado: (2022)

Degradation of Herpes Simplex Virus-1 Viral miRNA H11 by Vaccinia Virus Protein VP55 Attenuates Viral Replication
por: Zou, Weixuan, et al.
Publicado: (2020)

High accumulation of Mx2 renders limited multiplication of oncolytic herpes simplex virus-1 in human tumor cells
por: Ren, Yong, et al.
Publicado: (2021)

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
por: Liu, Yuanyuan, et al.
Publicado: (2022)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
por: Wang, Lei, et al.
Publicado: (2020)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
por: Schulz, Alexander, et al.
Publicado: (2022)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib
por: Zhu, Jingxuan, et al.
Publicado: (2020)

Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021)

Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
por: Scanlan, Hayle, et al.
Publicado: (2022)

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
por: Hu, Mingming, et al.
Publicado: (2023)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

MEK inhibition with trametinib is a successful therapy in ganglioglioma
por: Daniel, Eliza Baird, et al.
Publicado: (2020)

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
por: King, Alastair J., et al.
Publicado: (2013)

Stability and anti-tumor effect of oncolytic herpes simplex virus type 2
por: Wang, Yang, et al.
Publicado: (2018)

Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA
por: Boscheinen, Jan B., et al.
Publicado: (2019)

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion
por: Cockle, Julia V., et al.
Publicado: (2017)

Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer
por: Woo, Yanghee, et al.
Publicado: (2019)

The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies
por: Bernstock, Joshua D., et al.
Publicado: (2021)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Structural basis for the action of the drug trametinib at KSR-bound MEK
por: Khan, Zaigham M., et al.
Publicado: (2020)

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
por: Marconcini, Riccardo, et al.
Publicado: (2017)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
por: Takaoka, Hiroo, et al.
Publicado: (2011)

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy
por: Ning, Jianfang, et al.
Publicado: (2014)

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta
por: Wang, Jiani, et al.
Publicado: (2014)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
por: Megison, Michael L., et al.
Publicado: (2014)

Entry of Oncolytic Herpes Simplex Virus into Human Squamous Cell Carcinoma Cells by Ultrasound
por: Okunaga, Shusuke, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a1vnf780gvg150u8c8mvbf5j5e